Overview

This trial is active, not recruiting.

Condition carcinoma, non-small-cell lung
Sponsor Peking Union Medical College Hospital
Collaborator Peking University People's Hospital
Start date June 2010
Trial size 150 participants
Trial identifier NCT01382992, LCC001

Summary

EGFR mutations plays an essential role in EGFR-TKIs treatment. However, for some patients, tissue samples are not available. The purpose of this study is to determine whether blood sample is feasible for EGFR mutation detection.For late stage NSCLC, we hypothesis plasma sample is an alternative for detecting EGFR mutations.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model case-only
Time perspective retrospective
Arm

Primary Outcomes

Measure
To determine the consistence of EGFR mutation status in paired tissue and plasma samples
time frame: 3 months

Secondary Outcomes

Measure
To determine the EGFR mutation status in Chinese NSCLC
time frame: 3month

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - Non-small cell lung cancer - Available plasma and pathologically confirmed tissue slices(pre-chemo and pre-radio therapy) - Informed Consent Exclusion Criteria: - N/A

Additional Information

Principal investigator Mengzhao Wang, MD
Trial information was received from ClinicalTrials.gov and was last updated in June 2011.
Information provided to ClinicalTrials.gov by Peking Union Medical College Hospital.